Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Crescita Therpeutc ( (TSE:CTX) ) has issued an announcement.
Crescita Therapeutics has mutually terminated its licensing agreement with Croma Pharma GmbH for the commercialization of Pliaglis in several European and South American countries. This strategic decision allows Crescita to regain control over Pliaglis’s development and commercialization rights in these territories and explore new partnerships, while Croma rationalizes its product portfolio and pays Crescita €575,000.
Spark’s Take on TSE:CTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:CTX is a Neutral.
Crescita Therapeutics faces significant challenges with declining revenues and profitability, which impact its stock score. While the balance sheet is strong with low financial leverage, the overall financial performance is mixed. Technical analysis suggests a neutral to slightly bearish trend, and valuation is unattractive due to a negative P/E ratio. These factors contribute to a relatively low overall score.
To see Spark’s full report on TSE:CTX stock, click here.
More about Crescita Therpeutc
Crescita Therapeutics Inc. is a Canadian commercial dermatology company focused on growth and innovation. The company has in-house research and development, as well as manufacturing capabilities, offering a range of non-prescription skincare products and early to commercial stage prescription products. Crescita also owns proprietary transdermal delivery platforms for developing patented formulations to deliver active ingredients through the skin.
Average Trading Volume: 17,426
Technical Sentiment Signal: Sell
Current Market Cap: C$10.26M
For detailed information about CTX stock, go to TipRanks’ Stock Analysis page.